Coherus BioSciences (CHRS) Reports Q2 Loss of $1.56
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.34 +16.52%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($1.56), versus ($5.90) reported last year. Revenue for the quarter came in at $6.87 million, versus $4.46 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- 374Water Inc (SCWO) Misses Q2 EPS by 15c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
